Compliance Rate
Compliance Rate
100.0%
Compliant submissions
2
Incompliant submissions
0
Total trials
2
My Organizations' Clinical Trials
Showing 175 of 183 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/09
End: 12/31/11
Due: 12/31/12
Phase: N/A
Priority: Normal
Start: 02/28/11
End: 09/30/11
Due: 09/30/12
Phase: N/A
Priority: Normal
Start: 07/31/15
End: 11/30/16
Due: 11/30/17
Phase: N/A
Priority: Normal
Start: 03/31/14
End: 02/28/17
Due: 02/28/18
Phase: N/A
Priority: Normal
Start: 12/01/22
End: 08/31/23
Due: 08/31/24
Phase: N/A
Priority: Normal
Start: 01/31/08
End: 03/31/11
Due: 03/31/12
Phase: N/A
Priority: Normal
Start: 09/07/21
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 02/28/07
End: 08/31/12
Due: 08/31/13
Phase: N/A
Priority: Normal
Start: 02/04/16
End: 06/30/19
Due: 06/30/20
Phase: N/A
Priority: Normal
Start: 04/07/23
End: 02/28/26
Due: 02/28/27
Phase: N/A
Priority: Normal
Start: 01/31/04
End: 03/31/07
Due: 03/31/08
Phase: N/A
Priority: Normal
Start: 09/30/11
End: 07/31/16
Due: 07/31/17
Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)
Phase: N/A
Priority: Normal
Start: 03/01/25
End: 12/25/25
Due: 12/25/26
Phase: N/A
Priority: Normal
Start: 04/30/09
End: 07/31/10
Due: 07/31/11
Phase: N/A
Priority: Normal
Start: 05/31/25
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 03/31/09
End: 03/31/10
Due: 03/31/11
Phase: N/A
Priority: Normal
Start: 01/31/10
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 01/31/14
End: 06/30/19
Due: 06/30/20
Phase: N/A
Priority: Normal
Start: 02/08/24
End: 07/30/26
Due: 07/30/27
Phase: N/A
Priority: Normal
Start: 01/24/22
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 01/31/03
End: 02/28/09
Due: 02/28/10
Phase: N/A
Priority: Normal
Start: 10/07/24
End: 07/01/27
Due: 07/01/28
Phase: N/A
Priority: Normal
Start: 11/20/23
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 05/27/19
End: 04/15/20
Due: 04/15/21
Phase: N/A
Priority: Normal
Start: 08/01/25
End: 03/31/28
Due: 03/31/29